Recruiting

Daptomycin vs. Vancomycin

Sponsor:

Todd C. Lee MD MPH FIDSA

Code:

NCT06637332

Conditions

Staphylococcus Aureus Septicemia

Staphylococcus Aureus Bacteremia

S. Aureus Bacteremia

S. Aureus Bloodstream Infection

Staphylococcus Aureus Endocarditis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daptomycin for Injection

Vancomycin (IV)

Study Details

Brief summary:

This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.

This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)

Conditions

Staphylococcus Aureus Septicemia

Staphylococcus Aureus Bacteremia

S. Aureus Bacteremia

S. Aureus Bloodstream Infection

Staphylococcus Aureus Endocarditis

Study ID

NCT06637332

Start date

Nov 14, 2024

Status verified date

Aug, 2025

Completion date

Nov, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:

Inclusion Criteria:

  • Methicillin-resistant S. aureus bacteremia

Exclusion Criteria:

  • Severe allergy or non-severe rash to vancomycin or daptomycin
  • Suspected or confirmed MRSA pneumonia
  • Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Daptomycin

Daptomycin given by injection at a dose determined by the treating clinicians but no less than 6mg/kg

active comparator: Vancomycin

Vancomycin given by injection at a dose determined by the treating clinicians to achieve a trough-based or AUC-based target

Interventions

Daptomycin for Injection

Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg

Vancomycin (IV)

Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care

Primary outcome measure

  • Desirability of Outcome Ranking (DOOR) [ Time Frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119) ]

Central Contacts and Locations

Central contacts

Lina Petrella

514-934-1934lina.petrella@muhc.mcgill.ca

Locations

University of Alberta Hospital

Recruiting

Edmonton, Alberta, Canada

Contacts

Stephanie Smith, MD

ss@ualberta.ca

Principal Investigator:

Stephanie Smith, MD

Fraser Health Authority (Surrey Memorial Hospital)

Recruiting

Surrey, British Columbia, Canada, V3V1Z2

Contacts

Christopher Condin, PhD

christopher.condin@fraserhealth.ca

Principal Investigator:

Kevin Afra, MD

Newfoundland Health Services (Health Sciences Centre and St. Clare's Mercy Hospital)

Recruiting

St. John's, Newfoundland and Labrador, Canada

Contacts

Peter Daly, MD

pkd336@mun.ca

Principal Investigator:

Peter Daly, MD

Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital)

Recruiting

Hamilton, Ontario, Canada, L8L 2X2

Contacts

Dominik Mertz, MD

905-521-2100mertzd@mcmaster.ca

Principal Investigator:

Dominik Mertz, MD

Sunnybrook Health Sciences Centre

Recruiting

Toronto, Ontario, Canada, M4N 3M5

Contacts

Nick Daneman, MD MSc

Nick.Daneman@sunnybrook.ca

Principal Investigator:

Nick Daneman, MD MSc

Jewish General Hospital

Recruiting

Montreal, Quebec, Canada, H3T 1E2

Contacts

Leighanne Parkes, MD

leighanne.parkes@mcgill.ca

Principal Investigator:

Leighanne Parkes, MD

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)

Recruiting

Montreal, Quebec, Canada, H4A3S1

Contacts

Lina Petrella

5149341934lina.petrella@muhc.mcgill.ca

Principal Investigator:

Todd C Lee, MD MPH FIDSA

More Information

Sponsor

Todd C. Lee MD MPH FIDSA

Last update posted

Jul 31, 2026

Last verified

Aug, 2025

Keywords

  • S. aureus bacteremia
  • Methicllin resistant
  • MRSA
  • S. aureus bloodstream infection
  • Daptomycin
  • Vancomycin

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Todd C. Lee MD MPH FIDSA on 2026-07-31.